COVID-19 Impact On Global Stem Cell Therapy Market 2020 : Key Players, Trends, Share, Industry Size, Growth, Opportunities, Forecast To 2026 – Cole of…

The Pixion Market Research offers complete overview of the Global Stem Cell Therapy market with marketing knowledge on the basis of recorded data for marketing decision makers. Report also focuses on all the important aspects of the industry such as new models, opportunities and trends which enable more effective marketing decision making and theories with empirical insights from marketing study. Hence the report is beneficial for the readers as it informs about the crucial parameters and market developments in order to take steps accordingly and make marketing strategies.

Get Free Sample Of This Research https://www.pixionmarketresearch.com/report/global-stem-cell-therapy-market/1145/

The Research makes some important proposals for new projects of the industry before evaluating its feasibility. The report is also inclusive of different business models, quantitative analysis on the basis of various analytical tools. Hence the market size of the Global Stem Cell Therapy market is estimated over the forecast period. CAGR for the estimated period of time is forecasted in terms of revenue.

There are some key segments covered in this report such as product type, application, competitive landscape and key geographies.

This report focuses on the outlook of the industry on the basis of key applications and end users of the market.

Geographical analysis is one of the most important feature of any industry. This section majorly focuses of the key regions and countries which have good market of the industry. The major trends and developments taking place in the key regions are covered in this report. Hence, geographical analysis provides a deep insight about the opportunities and possibilities of generating revenue for the new entrants in the market.

The Report provides the industry analysis, estimation and extraction of the data based on the historic database for future status. It also covers the growth aspects of the market along with the restraining factors which are likely to impact on the overall the growth of market in the estimated forecast period. In addition, it also covers the demand and supply of the market research study in the estimated forecast period. Detailed study of the market players with their profile, sales analysis and competitive landscape is provided in the report. Furthermore, partnership, collaboration and mergers in the industry are mentioned for the ease of the study of the Global Stem Cell Therapy industry.

Request sample copy of Stem Cell Therapy market research at:https://www.pixionmarketresearch.com/report/global-stem-cell-therapy-market/1145/

The Stem Cell Therapy Market Report deals with following key objectives:

Purchase Link:https://www.pixionmarketresearch.com/checkout?id=1145

The impact of Coronavirus outbreak on the market industry is explained in this report. Covid-19 outbreak has climbed rapidly and it is likely pull the market down further in the upcoming years. Thus the complete overview of the pandemic is studied to help you understand the economic impact of the virus so far. Therefore, the strategies and solutions are discussed based on assessments made by different analysts and industry experts in order to stabilize the industry condition and grow further to maintain the status in the market.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs.

Continued here:
COVID-19 Impact On Global Stem Cell Therapy Market 2020 : Key Players, Trends, Share, Industry Size, Growth, Opportunities, Forecast To 2026 - Cole of...

Analysis on New Product Launches in Covid-19 Related Markets-Global Allergy Rhinitis Drugs Market 2020-2024 | Evolving Opportunities with Alcon Inc….

LONDON--(BUSINESS WIRE)--The global allergy rhinitis drugs market is expected to grow by USD 2.4 billion as per Technavio. This marks a significant market slowdown compared to the 2019 growth estimates due to the impact of the COVID-19 pandemic in the first half of 2020. However, steady growth is expected to continue throughout the forecast period, and the market is expected to grow at a CAGR of almost 4%. Request free sample pages

Read the 120-page report with TOC on "Allergy Rhinitis Drugs Market Analysis Report by Product (Antihistamines, Intranasal corticosteroids, Immunotherapies, and Others), Geographic Landscape (APAC, Europe, MEA, North America, and South America), and the Segment Forecasts, 2020-2024".

https://www.technavio.com/report/allergy-rhinitis-drugs-market-industry-analysis

The market is driven by the increasing prevalence of allergic rhinitis. In addition, rising awareness about allergic rhinitis is anticipated to boost the growth of the allergy rhinitis drugs market.

Allergic rhinitis, a common non-infectious rhinitis, affected 10%-40% of the population globally in 2017, according to a survey conducted by researchers of the Catholic University of Korea. In addition, about 12 million people diagnosed with allergic rhinitis, visited physicians in 2017, according to the CDC. A person suffering from this condition experiences various symptoms including rhinorrhea, sneezing, nasal pruritus, and nasal congestion. The prevalence of allergic rhinitis is increasing due to factors such as sedentary lifestyle and genetic factors. This is contributing to the increase in the number of visits to hospitals by patients and the consequent administration of allergic rhinitis therapeutics. Thus, the increasing prevalence of allergic rhinitis is expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Allergy Rhinitis Drugs Market Companies:

Alcon Inc.

Alcon Inc. operates the business under various segments such as Surgical and Vision Care. The company offers PATANASE, which is an olopatadine hydrochloride nasal spray. It is prescribed by physicians for patients, 12 years of age and older, to provide relief from symptoms of seasonal allergic rhinitis.

ALK-Abello AS

ALK-Abello AS offers is involved in the development and distribution of allergy treatment products. The company offers ACARIZAX, which is used for the treatment of house dust mite allergy. This condition is characterized by rhinitis.

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd. operates under various business segments, namely Global Generics, Pharmaceutical Services & Active Ingredients, and Proprietary Products. The company offers Vozet tablets, which is an oral formulation of levocetirizine. This medication is indicated for the treatment of chronic urticaria and allergic rhinitis.

GlaxoSmithKline Plc

GlaxoSmithKline Plc offers products through the following business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company offers Avamys/Veramyst, which is a synthetic corticosteroid. This medication is used for the treatment of allergic rhinitis.

Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. is involved in the development and production of gene therapy, regenerative medicines, and stem cell therapies. The company provides Ryaltris, which is fixed-dose combination nasal spray of an antihistamine and a steroid. This medication is indicated for patients, 12 years of age and older, suffering from seasonal allergic rhinitis.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Allergy Rhinitis Drugs Market Product Outlook (Revenue, USD Billion, 2020-2024)

Allergy Rhinitis Drugs Market Geographic Landscape Outlook (Revenue, USD Billion, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care Include:

Eye Allergy Therapeutics Market Global Eye Allergy Therapeutics Market by product (antihistamines, mast cell stabilizers, corticosteroids, immunomodulators, and others) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Go here to see the original:
Analysis on New Product Launches in Covid-19 Related Markets-Global Allergy Rhinitis Drugs Market 2020-2024 | Evolving Opportunities with Alcon Inc....

Novel Bispecific CD19/CD22 CAR-T Therapy Deemed Tolerable in Relapsed/Refractory ALL – Oncology Nurse Advisor

A novel, bispecific CD19/CD22 chimeric antigen receptor T-cell (CAR-T) therapy was tolerable and resulted in responses among patients with acute lymphoblastic leukemia (ALL), according to results from a phase 1 trial presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting I 2020.

Thenovel CAR-T therapy was developed with the hypothesis that dual antigen-targetingstrategies may prevent antigen negative escape, Haneen Shalabi, DO, of theNational Cancer Institute and lead author and presenter of the study, said.

Thephase 1, dose-escalation study treated 13 young patients with ALL with theCD19/CD22 CAR-T therapy at 3 different dose levels, including 3 x 105,1 x 106, and 3 x 106. The bispecific construct containedFMC63 (CD19 scFv) linked with m971 (CD22 scFv) and a 4-1 BB costimulatorydomain.

Patientsunderwent lymphodepletion with fludarabine plus cyclophosphamide prior to theirCAR-T infusion. The primary endpoints were safety and toxicity, and thesecondary endpoints were efficacy, chimeric antigen receptor (CAR) expansion,and CAR persistence.

Atbaseline, the median age was 19.6 (range, 5.4-28.5). Patients had receivedprevious treatments, including hematopoietic stem cell transplant (54%),CD19-targeted therapy (69%), prior CD19 CAR T cell therapy (38.4%),blinatumomab (61.5%), CD22-targeted therapy (38.4%), inotuzumab (30.7%), andCD22 CAR-T therapy (15.4%). Extramedullary disease was present in 46.2% ofpatients.

CAR Tcells were well tolerated and toxicities were reversible in all patients, DrShalabi said.

Cytokinerelease syndrome (CRS) developed in 46% of patients, 15.4% of which was grade 3or higher. Both patients who developed grade 3 or higher CRS had received the 1x 106 dose level of the CD19/CD22 CAR-T product and both requiredtreatment with tocilizumab. One patient developed neurotoxicity, and hadreceived the 3 x 106 dose level.

Of the12 patients evaluable for efficacy, a complete response (CR) was achieved by42% (5) of patients, including all patients who received the 1 x 106 or 3 x 106 dose levelsof the CD19/CD22 CAR-T therapy. There were 2 nonresponders.

Two patientswho received 1 x 106 CAR-T and all patients who received the 3 x 106dose level were negative for minimal residual disease (MRD), with the remainingCRs demonstrating bone marrow clearance. Four of the 5 patients who were MRDnegative were also naive to CAR-T therapy.

Of the 5patients who achieved a CR, 2 relapsed with CD19-positive/CD22-positive diseaseand 3 remained in remission at a median 7 months after CAR T cell infusion.

Severalpatients, however, who were MRD negative in the bone marrow did not achieve CRin their extramedullary disease. Dr Shalabi said that these discrepant resultsbetween marrow and extramedullary disease suggests potentially limited CAR-Ttrafficking to sites of extramedullary disease. She suggested that treatmentat higher dose levels may be needed to overcome this limitation.

CAR T-cellexpansion occurred in all patents who responded, with a median peak inperipheral blood of 7%. At day 28, there were 1.3% CAR T cells in the bonemarrow. The persistence of the CAR T cells in peripheral blood was a median of45.6 days, as measured by flow cytometry.

Dr Shalabi concluded that this early experience with bispecific CD19/CD22 CAR T cells demonstrates clinical activity with reversible CRS and limited neurotoxicity. She noted that future studies will explore a 1 x 107 dose level, intensification of lymphodepletion prior to CAR-T infusion, and consideration of the potential role of immune checkpoint inhibitors to augment CAR-T in extramedullary disease.

References

Shalabi H, Yates B, Shahani S, et al. Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refractory ALL. Presented at: American Association for Cancer Research (AACR) Virtual Annual Meeting I 2020; April 27-28, 2020. Abstract CT051.

This article originally appeared on Cancer Therapy Advisor

Link:
Novel Bispecific CD19/CD22 CAR-T Therapy Deemed Tolerable in Relapsed/Refractory ALL - Oncology Nurse Advisor

Animal Stem Cell Therapy Market Research, Recent Trends and Growth Forecast 2025 – ZZReport

This report also researches and evaluates the impact of Covid-19 outbreak on the Animal Stem Cell Therapy industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Animal Stem Cell Therapy and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Latest Market Research Report onAnimal Stem Cell Therapy Market size | Industry Segment by Applications (Veterinary Hospitals and Research Organizations), by Type (Dogs, Horses and Others), Regional Outlook, Market Demand, Latest Trends, Animal Stem Cell Therapy Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

The report also assesses driving forces of Animal Stem Cell Therapy market and changing dynamics which have been examined as growth-boosting factor. Also, the Animal Stem Cell Therapy study sheds light on limitations and restraints that could probably become obstruction while the Animal Stem Cell Therapy industry is proceeding to achieve substantial revenue. The report also aids readers to gain in-depth knowledge of a Animal Stem Cell Therapy market environment that comprises terms such as entry barriers, and trading policies as well as regulatory, political, financial and social concerns that may also hamper Animal Stem Cell Therapy market growth momentum.

Request Sample Copy of this Report @ https://www.zzreport.com/request-sample/1189

It also facilitates clients with the acumen to gain competitive advantages in the Animal Stem Cell Therapy market and the strengths and weaknesses of their strong opponents. The Animal Stem Cell Therapy report emphasizes their strategic movements including brand expansions, public relations activities and product releases. The report highlights ideas, objectives, core business values, and niche markets of leading contributors operating in the worldwide Animal Stem Cell Therapy industry.

Manufacturer / Potential Investors, Traders, Distributors, Wholesalers, Retailers, Importers and Exporters, Association and government bodies are the main audience for Animal Stem Cell Therapy market involved in this report.

Report Scope:

Animal Stem Cell Therapy market competition by top Manufacturers:

Animal Stem Cell Therapy Market Outlook by Applications:

Animal Stem Cell Therapy Market Statistics by Types:

The study includes the profiles of key players in the Animal Stem Cell Therapy market with a significant global and/or regional presence. The study on the global Animal Stem Cell Therapy market includes qualitative factors such as drivers, restraints, and opportunities. The study covers the qualitative and quantitative analysis of the market segmented based on type, technology, and vertical. Moreover, the study provides similar information for the key geographies.

With the clear insight this report also helps in understanding Animal Stem Cell Therapy market dynamics, structure by analyzing the Animal Stem Cell Therapy market segments, and project the Animal Stem Cell Therapy market size. Actual market sizes and forecasts have been provided for all the above-mentioned segments.

The foremost points are labelled in detail which are covered in this Animal Stem Cell Therapy Market Report:

The Animal Stem Cell Therapy Analysis report offers an entire substantial study of the Animal Stem Cell Therapy market, key tactics followed by leading Animal Stem Cell Therapy industry Players and impending segments. The previous and current Animal Stem Cell Therapy industry forecast analysis in terms of volume and value along with research conclusions is a decisive part of Animal Stem Cell Therapy market analysis report.

Request Customization on This Report @ https://www.zzreport.com/request-for-customization/1189

Read more:
Animal Stem Cell Therapy Market Research, Recent Trends and Growth Forecast 2025 - ZZReport

Coronavirus: UAE’s stem cell treatment fights symptoms of Covid-19, not cure it – Khaleej Times

Researchers call the treatment national achievement but clarify that it is supportive, not

Clinical trail for the new treatment for Covid-19 using stem cells is underway for the first time in the UAE, Dr Fatima Al Kaabi, Head Hematology and Oncology, Sheikh Khalifa Medical City, said on Saturday.

She said the breakthrough by the Abu Dhabi Stem Cell Center is a national achievement.

"Up to 28 specialist and researchers formed the team that came up this treatment," said Dr Fatima, who is also an assistant researcher at stem cell project.

Addressing a press conference on Saturday, the official clarified that new breakthrough supports and doesn't entire cures a patient during treatment period.

"We have utilised all our scientific potentials to deal with Covid-19 crisis. We are proud to have developed this new treatment. It is undergoing clinical trials for first time in the UAE. It's a national achievement. This treatment is supportive and doesn't provide entire cure. It helps patients overcome the symptoms caused by the virus but doesn't kill it.

The treatment involves extracting stem cells from the patient's own blood and reintroducing them after activating them. It is expected to add to the global efforts to contain the spread of Covid-19 and to ensure the health and safety of the people of the world.

The new treatment was first experimented on a patient on April 4. And so far, 73 patients have been treated by stem cells with 25 per cent in the ICU.

"We are about to conclude the collection of data to conduct further comparative experiment and compare them with patients who have not received the treatment. We will compare both groups of patients who have received the stem cells treatment and those who haven't. Now next step will be more practical and efficient."

What is stem cell treatment?

Elaborating further on stem cells research and how the treatment was a success, she said: "Stem cells exist in human body with similar characteristics. One of the characteristics is to transform to different kind of cells, reproduce limitlessly, producing more similar stem cells. We isolated one type of primitive stem cells, called embryonic stem cells, which researchers believed to be having renewing potential. We think, it can renew the damage cells and adjust its response to reduce its inflammation caused by Covid-19 in lung tissue and contribute to auto-renewing damaged cells. The advantage of using this cell is that their collection doesn't necessitate a surgical operation as is the case in other type of stem cells. But we only take a blood sample from the patient and inject it in lungs without a surgical intervention but only with a stem cell nebulisation. After taking the blood sample and extracting cells from it, it undergoes a chemical process where platelets responsible for growth in the patient are used to activate, modulate cells, and reinsert them in the lungs of the patients," said Dr Fatima.

Children have more resistance to Covid-19

Dr Alawi Al Sheikh, UAE spokesman for the Advanced Science sector, noted that massive work is ongoing with the UAE scientific community working in cohesion.

He underlined the efforts of Mohammed Bin Rashid University of Medicine and Health Sciences and Al Jalila Children's Specialty Hospital and the University of Sharjah in undertaking various studies, which revealed that children are more resistance than seniors to Covid-19.

"We tried to conduct a number of studies to understand how cells contract the disease. The cell surfaces contain receptors. These are gates which can grant access to some but not all to enter. Some of these cells are in respiratory system. Once virus enters respiratory system, it enters its genome characteristics, and overtakes functions of cells, like producing proteins, multiplying DNA, the cell then become a factory of viruses. The abundance of viruses means the immune system will exert more effort to fight the intruders and by doing that the gravity and severity of the case continues," Dr Alawi said.

"One of the studies we did look at was weak spread of virus among children compared to seniors. The study found out that receptors are less in tissues of nose and lung cells of children compared to seniors. Due to less number of receptors in the cells, these contribute to the minimising and limiting the spread of disease among children. The study also found that number of receptors increases among smokers and people from asthma, respiratory problems and other issues like hypertension."

New cases announced

The UAE on Saturday announced 561 new Covid-19 cases and 121 recoveries. The UAE Ministry of Health and Prevention also revealed that 22 people of determination were also reported as positive in past two weeks.

"In the past two weeks, we have registered an average of 29,000 tests daily. There were 36,366 new tests conducted on Saturday. There were 561 new cases taking the total to 13,599. As many as 121 patients recovered. Till date there are 2,664 total recoveries. But 8 new deaths were reported taking total to 119 deaths. Most of the deaths were due to complications and chronic diseases. As many as 10,816 patients still receive care," said Dr Amna Al Dahak Al Shamsi, official spokesperson, the UAE Government. Dr Amna urged families of people of determination can call 02-5968689 to book appointment for home tests for Covid-19.

ashwani@khaleejtimes.com

Ashwani Kumar

Continue reading here:
Coronavirus: UAE's stem cell treatment fights symptoms of Covid-19, not cure it - Khaleej Times

Dr. David C. Karli’s Opinion on Regenerative Medicine and Age Prevention | – SpaceCoastDaily.com

Aging is an inevitable process. We cannot escape or prevent getting older but what if theres a fascinating field of medicine that can manage the aging process and prolong our health and vitality and longevity as we age?

Aging is an inevitable process. We cannot escape or prevent getting older but what if theres a fascinating field of medicine that can manage the aging process and prolong our health and vitality and longevity as we age?

Keeping in mind that there may never be an approach to totally stop or reverse aging, there have been some surprising disclosures to how Regenerative Medicine can naturally heal our body without the use of any surgical procedure.

Rejuvenating Old Cells to Healthy ones

The paces, stresses, and complexities in life drive us to age prematurely thereby breaking down our cells. Cell breakdown may lead to several health conditions like cancer, heart disease, Alzheimers and others.

Driving our bodies to age quickly, cell-breakdown is host to many age-related diseases, causing more than 100,000 deaths per day.

Dr David C Karli is an Ivy-trained physician, specialized in treating athletic injuries by inducing regenerative medicine and stem cell therapy in treatments.

He accepts the fact that patients can increase an additional 30 years of life by using Regenerative Medicine. One such innovation uses stem cells, however, there are issues with these cells.

They may not replace the original, diseased cells rapidly enough, or they may start to replicate uncontrollably, bringing about malignant growth.

Yet, Regenerative Medicine definitely guarantees the complete curing of a wide range of diseases, and ideally, slowing down the aging process too.

Stem Cell Therapy Programs with Promising Results

With solid funding and rapid advancements, one stem cell therapy that promises great outcomes is transfusions. In this therapy, stem cells are extracted from the patient and grown in cell culture to increase the number of cells. Following this, those cells are injected back into the patients body.

Dr. Karlis keen interest in Transfusions led him to create biologic products that can cause an age-related decline in a persons strength, endurance, and various other physical abilities.

At his biotech firm, Greyledge Technologies, biologic products are prepared by processing materials (blood or bone marrow) and implanting them into the human body to replicate the diseased tissues.

With an FDA-registered laboratory environment, the outcomes are promising and are an anti-aging protocol.

Telomeres may be the next-gen solution for Anti Aging

Telomeres are essential parts of our DNA that are connected to the premature aging cells. Situated at the end caps of our DNA strands, the information within Telomeres is lost while DNA replicates to the extent that they stop replicating.

If DNA replicates without losing information, scientists believe that Telomeres can significantly help to slow down the aging process.

Similar is the case with Metformin, a pharmaceutical reagent that improves wound healing. Proven to counteract aging, Metformin is now being tested for its unique ability to mimic calorie restriction.

Anti-Aging Through Regeneration

Utilizing induced tissue regeneration, this technology is a new approach to anti-aging treatment. Combining telomerase therapy and induced tissue regeneration, anti-aging through regeneration includes the study of the impact on age-related diseases like diabetes, metabolic disorders, cardiovascular disease, and others.

This technique focuses on the cells that are generated in our body during youth. As we age, these cells are lost and lead to a metabolic imbalance.

Scientists and Researchers are trying to find a way in which these cells can be restored to reverse the signs of aging and create a balance.

Humans have the ability to regenerate damaged and diseased tissues. However, this only happens during the first few weeks of development. With the help of Artificial Intelligence, scientists are trying to unlock this potential ability in humans.

The Future of Anti-Aging

With several breakthroughs on the horizon, cure-all promises and best outcomes, these anti-aging protocols have a long way to go.

While the introduction of regenerative medicine and stem cell therapies to redefine orthopedic treatment sounds like a miracle, there are still unexplored paths that need to be taken.

With all the benefits regenerative medicine has to offer, there will always be an eye on the never-ending search for the fountain of youth.

CLICK HERE FOR BREVARD COUNTY NEWS

Go here to read the rest:
Dr. David C. Karli's Opinion on Regenerative Medicine and Age Prevention | - SpaceCoastDaily.com

This startup aims to treat coronavirus using stem cell research – YourStory

In its fourth week now, C-CAMPs Covid Innovation Deployment Accelerator (C-CIDA) continues to select top startups across India innovating to fight the coronavirus pandemic. It has managed to select and showcase 30 startups in 30 days that are solving gaps and needs across screening, monitoring, and diagnostics.

Several of these are usingstem cell research. One of them is Bengaluru-based cell therapy startup Eyestem. Founded by Jogin Desai, Rajani Battu, and Dhruv Sareen, the startup aims to develop scalable cell replacement therapies for the world.

Hence, Eyestem believes that the easiest way forward is to repurpose existing drugs and has built an Anti-Covid screening (ACS) platform, which aims to provide the research community with a resource to determine the efficacy of a drug or a vaccine using the closest human host cell population.

Led by Rajarshi Pal, Chief Scientist of Eyestem, the startup had been working on lung cells for a couple of years now, publishing papers on the same. However, in the last three months, it pivoted to build this platform specifically to fight the coronavirus pandemic.

Now, it is ready to partner with other labs and companies to grow SARS-CoV-2 virus in these lung cells and start testing these drugs.

He claims that the startup has already collaborated with two players, and is also expecting to start working with facilities in the US soon.

How has the coronavirus outbreak disrupted your life? And how are you dealing with it? Write to us or send us a video with subject line 'Coronavirus Disruption' to editorial@yourstory.com

Read more from the original source:
This startup aims to treat coronavirus using stem cell research - YourStory

The disease that wastes away boys muscles – Standard Digital

Fifteen years ago, Scholar Muthamia was getting ready to welcome her second child. The pregnancy had no complications at all and when her son Ferdinand Mutugi Njuguna was born, he weighed a healthy 3.9 kg.Mutugi was as precocious a toddler as can be, and all was fine in the Njuguna household until the boy developed a peculiar walking style.He would push his left foot ahead while walking and he didnt seem to quite stand up straight, Muthamia says.We thought it was a unique walking style he had developed, and let him be. And weirdly, when wearing a pair of shorts or trousers, he would pull them up with his arms while walking and many assumed we were buying him over-sized clothes, she says.Later, Ferdinand began falling while walking. He also started having a hard time standing up from a sitting position. Climbing stairs became a hardship and he couldnt run as fast as he used to.He would get tired very fast and even started walking on his toes. We took him to various hospitals and eventually ended up at Kenyatta National Hospital where he was diagnosed with Duchenne muscular dystrophy,she says.

For More of This and Other Stories, Grab Your Copy of the Standard Newspaper. Read Now

Do not miss out on the latest news. Join the Standard Digital Telegram channel HERE.

Read this article:
The disease that wastes away boys muscles - Standard Digital

Easing of restrictions is welcome, but they must be carried out carefully – The National

I write to you in reference to your article Coronavirus latest: WHO urges countries to ease lockdowns slowly (May 2). This is a meaningful and thought-provoking piece. Lockdown measures have been in place all over the world for a good while now, and many nations are ready to open up their economies. At the same time, if they do it too hastily, and people stop following physical distancing and hygiene rules overnight, experts have warned that it is likely a second wave of infections will hit. Eased restrictions must be carried out in stages, and with great care. The world economy has already been shattered, and prolonging the lockdowns will take a toll on both our morale and the economy. India is taking this challenge head-on and easing restrictions carefully. I hope that in the coming days, a sense of normalcy will return to India.

K Ragavan, Bengaluru

Rishi Kapoor: your legendary memory lives on

Please refer to the news item Beloved Bollywood star Rishi Kapoor dies aged 67 by Farah Andrews (April 30) about the sad passing away of Rishi Kapoor, a popular and versatile Indian actor. Kapoor was a beloved actor and an outspoken artist. He starred in numerous films, commencing with Mera Naam Joker and then later the cult film Bobby. He was the romantic hero of the 1970s and 80s, and his talents went beyond acting. Dancing also came naturally to him, as it did to all the members of his family. His book Khullam Khulla is an enriching read, too. Kapoor was loved by his fans. He had rivals, but no enemies.

He further proved his histrionic skills and talents in some of the films in which played major roles in the past decade, such as D-Company and Mulk. I am sure his son Ranbir Kapoor will carry on the great tradition of brilliant acting, for which the Kapoor dynasty is renowned. My condolences to his wonderful family.

Rajendra Aneja, Dubai

Abu Dhabi stem cell treatment gives us hope

I write to you in reference to a video posted on The National's Facebook page with the following caption: UAE researchers develop promising breakthrough Covid-19 treatment (May 2).

What an amazing achievement. We urgently need to find an effective treatment to combat the spread of this deadly virus.

Dr Rahmath Mohammad, Sri Lanka

I am confident this will be the best innovation in the fight against coronavirus, and is it all thanks to the UAE's rulers.

Mark Mich, Dubai

Updated: May 2, 2020 06:49 PM

More here:
Easing of restrictions is welcome, but they must be carried out carefully - The National

Moderna Covid Drug Production Deal, And Other News: The Good, Bad And Ugly Of Biopharma – Seeking Alpha

Moderna Boosts Production with Lonza Deal

Moderna Therapeutics (MRNA) announced its new collaboration with Lonza for boosting its production capacity for mRNA 1273. The company had recently struck a deal with the federal government to focus on developing COVID 19 vaccine candidate. The company stands to receive $483 million from BARDA for accelerating the development of the vaccine. Moderna dosed the first patient under its Phase I clinical trial in March.

Under the latest deal with the Swiss firm, Moderna will be able to use Lonza manufacturing facilities in the United States and Switzerland. It is expected that the technology transfer may be started in June while the batch production in the United States may begin in July. Moderna CEO Stphane Bancel said, This long-term strategic collaboration agreement will enable Moderna to accelerate, by 10 times, our manufacturing capacity for mRNA-1273 and additional products in Modernas large clinical portfolio. Lonzas global presence and expertise are critical as we scale at unprecedented speed." The agreed longevity of the deal is 10 years and will involve creations of manufacturing suites at various Lonza manufacturing sites.

Moderna also recently announced that it has submitted with the FDA its plan to start Phase 2 and later stage trials of the vaccine candidate. The company has received early feedback for its Phase 2 study design. It is anticipated that the dosing for Phase 2 may start during the second quarter. The company is looking to enroll 600 healthy subjects for assessing the safety and efficacy of the shot with doses administered 28 days apart. Currently, there are a number of pharma companies in the race to produce vaccine for fight against COVID 19.

In response to the latest deal, Lonza chairman and CEO ad interim Albert Baehny said, The current pandemic illustrates the need to combine the best science with resilient supply chains that can scale. We are fully committed to leveraging our global network and experience in manufacturing technologies to support Modernas manufacture of mRNA-1273 as well as collaborating on future Moderna products.

Modernas collaboration with US Biomedical Advanced Research and Development Authority (BARDA) involves development of mRNA 1273, which is an mRNA vaccine that encodes for a prefusion stabilized form of the Spike (NYSE:S) protein. BARDA is a division of the Department of Health and Human Services and its funding will support late stage clinical development programs for the vaccine. In order to scale up, Moderna anticipates to hire up to 150 new employees, including engineers, clinical staff and manufacturing staff.

The companys new tie up with Lonza is expected to allow the manufacturing of up to a billion doses per year. Lonza is based out of Basel in Switzerland.

Marker Therapeutics (MRKR) announced that the FDA has granted Orphan Drug designation to its acute myeloid leukemia drug candidate MT 401. The orphan drug candidate offers several benefits such as tax credits for qualified clinical trials and 7 years of market exclusivity if the drug candidate is approved. The FDA generally grants this tag to novel biologics and drugs aiming to provide safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the United States.

MT 401 is a multi-tumor associated antigen-specific T cell based product developed for treating AML following allogeneic stem cell transplant. The company CEO and President Peter Hoang said, In investigator-sponsored trials, our MultiTAA-specific T cell product candidate was well-tolerated and we have observed clinical benefit across various liquid and solid tumors, suggesting the product candidate's ability to induce a patient's own T cells to expand for a more durable anti-tumor effect. The drug candidate has been given the tag for treating hematological malignancies and solid tumor indications.

Marker Therapeutics reported that it is planning to start its Phase 2 study in subjects with post allegeneic stem cell transplant AML. T cells are obtained from healthy donors and are made to undergo a two-step cell culture process. The process leads to creation of CD4 and CD8 cell mixture which is able to identify multiple tumor specific antigens.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing next-generation T cell-based immunotherapies for treating hematological malignancies and solid tumor indications. The companys technology relies upon selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. However, Marker does not genetically engineer its T Cell therapies and therefore its drug candidates are expected to be less expensive to manufacture.

Jazz Pharmaceuticals Plc (JAZZ) reported that it has halted the enrolment in its Phase 3 clinical study of defibrotide. The company stated that the decision was taken on the recommendation of an Independent Data Monitoring Committee (IDMC) which opined that the study is highly unlikely to produce statistical significance for the primary endpoint of VOD-free survival at Day +30 post-HSCT in the final analysis.

Jazz Pharmaceuticals further stated that the IDMC reached the said recommendation after completing pre-planned interim analysis of the initial 280 patients and where the protocol-specified futility criteria were met. Robert Iannone, M.D., M.S.C.E., executive vice president, research and development of Jazz Pharmaceuticals said, "While enrollment has been discontinued, the trial will run to completion through the follow-up of the more than 370 patients enrolled. VOD is a rapidly progressive and devastating condition that can develop following stem-cell transplantation. As the only approved treatment with demonstrated efficacy based on survival at 100 days after HSCT, defibrotide is an important medicine for this patient population." The company has notified relevant authorities about the decision of discontinuance.

The company stated that the patients already enrolled in the study may be allowed to continue participation if deemed appropriate after further investigation. The relevant Phase 3 was not intended to further assess defibrotide for the treatment of VOD and does not impact the approved indication or other ongoing clinical studies. The Phase 3 study was a randomized, open-label, multi-center trial with an adaptive design. The main aim of the study is to compare the efficacy of defibrotide versus best supportive care in the prevention of hepatic VOD.

Jazz Pharmaceuticals mainly aims to develop medicines for critical diseases with limited treatment options. The main focus of the company is on neuroscience and oncology including movement disorders, sleep medicine and hematologic tumors.

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, weve positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Read the rest here:
Moderna Covid Drug Production Deal, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha